Kris Cameron Wood

Kris Cameron Wood

Associate Professor of Pharmacology and Cancer Biology

Our laboratory uses genomic and pharmacological approaches to understand how tumor dependencies are shaped by cell intrinsic factors, environmental factors, and drug treatments during the dynamic process of tumor evolution. To learn more, please visit our laboratory website: https://woodlabduke.com/.

Appointments and Affiliations

  • Associate Professor of Pharmacology and Cancer Biology
  • Associate Professor of Cell Biology
  • Core Faculty in Innovation & Entrepreneurship
  • Member of the Duke Cancer Institute

Contact Information

  • Email Address: kris.wood@duke.edu
  • Websites:

Education

  • Ph.D. Massachusetts Institute of Technology, 2007

Courses Taught

  • CMB 710B: Cell & Molecular Biology Module II
  • CMB 710E: Cell & Molecular Biology Module V
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis
  • PHARM 393: Research Independent Study
  • PHARM 394: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 495: Research Independent Study
  • PHARM 818: Molecular Mechanisms of Oncogenesis
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I

In the News

Representative Publications

  • Ang, HX; Sutiman, N; Deng, XL; Liu, A; Cerda-Smith, CG; Hutchinson, HM; Kim, H; Bartelt, LC; Chen, Q; Barrera, A; Lin, J; Sheng, Z; McDowell, IC; Reddy, TE; Nicchitta, CV; Wood, KC, Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13., Proc Natl Acad Sci U S A, vol 120 no. 38 (2023) [10.1073/pnas.2221448120] [abs].
  • Killarney, ST; Tait, SWG; Green, DR; Wood, KC, Sublethal engagement of apoptotic pathways in residual cancer., Trends Cell Biol (2023) [10.1016/j.tcb.2023.07.005] [abs].
  • Stanland, LJ; Ang, HX; Hoj, JP; Chu, Y; Tan, P; Wood, KC; Luftig, MA, Supplementary Figure Legends 1-7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer (2023) [10.1158/1541-7786.23912456] [abs].
  • Stanland, LJ; Ang, HX; Hoj, JP; Chu, Y; Tan, P; Wood, KC; Luftig, MA, Figure S2 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer (2023) [10.1158/1541-7786.23912474.v1] [abs].
  • Stanland, LJ; Ang, HX; Hoj, JP; Chu, Y; Tan, P; Wood, KC; Luftig, MA, Table S4 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer (2023) [10.1158/1541-7786.23912444.v1] [abs].